Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.

Susan N. Chi,Franck Bourdeaut,Theodore W. Laetsch,Maryam Fouladi,Margaret E. Macy,Guy Makin,Neerav Shukla,Cynthia Wetmore,Ashley Margol,Michela Casanova,Lindsay Kilburn,Joanna Yi,Darren Hargrave,Geoffrey McCowage,Navin Pinto,David H. Ebb,Giles W. Robinson,Laura Sierra,Melinda S. Merchant,Karsten Nysom

Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.

2020

10525Background: Absence of integrase interactor 1 (INI1) expression is a defining molecular feature of rhabdoid tumors (RT), epithelioid sarcoma (ES), and chordomas, inducing dependence on enhance...

Keywords:

Integrase interactor 1
Tazemetostat
phase i study
Pathology
EZH2
Cancer research
Medicine
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations